ArticleMolecular diversity2026
Vasicine derivatives as potent MAPK inhibitors for psoriasis treatment.
Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Vasicine-Based Synergistic Antifungal Agents against FLC-ResistantACS medicinal chemistry letters · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Psoriasis is a common polygenic hereditary skin disease and difficult to cure. Vasicine is an active alkaloid from Chinese herbal medicine Justicia adhatoda L. In present work, we have prepared a series of vasicine derivatives, and anti-inflammatory activities in vitro and in vivo have been evaluated. The in vitro results revealed that derivatives showed good anti-inflammatory activity of inhibiting NO generation. In vivo studies indicated that 4r could alleviate imiquimod induced skin inflammation, reduce the thickness of the epidermis and pathological lesions. Mechanism research showed that 4r could attenuate psoriasis-like skin inflammation via inhibiting MAPK signaling pathway activation, and alleviate LPS-induced inflammation in HaCat cells. Molecular docking study demonstrated that 4r could effectively bind to the active pocket of target MAPK protein 4U3Y and 5J5T. Therefore, vasicine derivatives may be considered as potent MAPK inhibitors for psoriasis treatment.
Indexed as
Identifiers
41269571What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.